---
title: "Hunan Hansen Pharmaceutical Co.,Ltd. (002412.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002412.SZ.md"
symbol: "002412.SZ"
name: "Hunan Hansen Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-04-15T11:27:31.745Z"
locales:
  - [en](https://longbridge.com/en/quote/002412.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002412.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002412.SZ.md)
---

# Hunan Hansen Pharmaceutical Co.,Ltd. (002412.SZ)

## Company Overview

Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers digestive system medicines; cardiovascular and cerebrovascular medicines; kidney-tonifying and urine-reducing medicines; trauma medicines; diagnostic medicines, etc. It provides medicines in injection, mixture, tablet, capsule, granule, syrup, decoction, tincture, and pill forms.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.hansenzy.com](https://www.hansenzy.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:12.000Z

**Overall: B (0.36)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 62 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.90% |  |
| Net Profit YoY | -23.90% |  |
| P/B Ratio | 1.47 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3313875440.52 |  |
| Revenue | 1048988405.94 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.89% | B |
| Profit Margin | 16.36% | A |
| Gross Margin | 78.74% | A |
| Revenue YoY | 8.90% | B |
| Net Profit YoY | -23.90% | D |
| Total Assets YoY | 4.48% | C |
| Net Assets YoY | 7.59% | B |
| Cash Flow Margin | 89.30% | C |
| OCF YoY | 8.90% | B |
| Turnover | 0.42 | C |
| Gearing Ratio | 11.77% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hunan Hansen Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.90%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-23.90%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.47",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3313875440.52",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1048988405.94",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.89%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "16.36%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "78.74%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "8.90%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-23.90%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.48%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.59%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "89.30%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "8.90%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "11.77%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 19.31 | 35/222 | 20.07 | 19.16 | 17.32 |
| PB | 1.47 | 33/222 | 1.55 | 1.49 | 1.42 |
| PS (TTM) | 3.16 | 78/222 | 3.34 | 3.22 | 3.08 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 04 | Salubris (002294.SZ) | B | C | C | A | B | B |
| 05 | Haisco (002653.SZ) | B | B | B | B | A | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002412.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002412.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002412.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002412.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**